HSV-1 Hijacks the Host DNA Damage Response in Corneal Epithelial Cells through ICP4-Mediated Activation of ATM.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
8
1
2021
Statut:
ppublish
Résumé
Herpes simplex virus type I (HSV-1) infection of corneal epithelial cells activates ataxia telangiectasia mutated (ATM), an apical kinase in the host DNA damage response pathway, whose activity is necessary for the progression of lytic HSV-1 infection. The purpose of this study is to investigate the mechanism of ATM activation by HSV-1 in the corneal epithelium, as well as its functional significance. Mechanistic studies were performed in cultured human corneal epithelial cell lines (hTCEpi, HCE), as well as in esophageal (EPC2) and oral (OKF6) cell lines. Transfection-based experiments were performed in HEK293 cells. HSV-1 infection was carried out using the wild-type KOS strain, various mutant strains (tsB7, d120, 7134, i13, n208), and bacterial artificial chromosomes (fHSVΔpac, pM24). Inhibitors of ATM (KU-55933), protein synthesis (cycloheximide), and viral DNA replication (phosphonoacetic acid) were used. Outcomes of infection were assayed using Western blotting, qRT-PCR, immunofluorescence, and comet assay. This study demonstrates that HSV-1-mediated ATM activation in corneal epithelial cells relies on the viral immediate early gene product ICP4 and requires the presence of the viral genome in the host nucleus. We show that ATM activation is independent of viral genome replication, the ICP0 protein, and the presence of DNA lesions. Interestingly, ATM activity appears to be necessary at the onset of infection, but dispensable at the later stages. This study expands our understanding of HSV-1 virus-host interactions in the corneal epithelium and identifies potential areas of future investigation and therapeutic intervention in herpes keratitis.
Identifiants
pubmed: 32543665
pii: 2770144
doi: 10.1167/iovs.61.6.39
pmc: PMC7415316
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Subventions
Organisme : NIDDK NIH HHS
ID : F30 DK094612
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE024006
Pays : United States
Références
Invest Ophthalmol Vis Sci. 2014 Feb 03;55(2):706-15
pubmed: 24370835
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7871-6
pubmed: 12796511
Virology. 2014 Mar;452-453:52-8
pubmed: 24606682
J Virol. 2004 May;78(9):4783-96
pubmed: 15078960
J Mol Biol. 1991 Jun 5;219(3):451-70
pubmed: 1646893
J Virol. 1985 Nov;56(2):558-70
pubmed: 2997476
J Virol. 1983 Jan;45(1):397-407
pubmed: 6296445
J Virol. 1991 Jan;65(1):299-307
pubmed: 1845890
J Virol. 1989 Nov;63(11):4579-89
pubmed: 2552142
J Virol. 2011 Jun;85(12):5733-44
pubmed: 21450820
J Biol Chem. 2001 Jan 26;276(4):2905-13
pubmed: 11069901
J Virol. 2007 Sep;81(17):9230-7
pubmed: 17581987
Clin Infect Dis. 2005 Aug 1;41(3):320-6
pubmed: 16007528
Ophthalmic Res. 2015;53(2):55-64
pubmed: 25531207
J Virol. 1982 Dec;44(3):1084-7
pubmed: 6294324
Hum Gene Ther. 1998 Dec 10;9(18):2787-94
pubmed: 9874276
Clin Exp Ophthalmol. 2010 Apr;38(3):227-8
pubmed: 20447115
Trends Microbiol. 2007 Mar;15(3):119-26
pubmed: 17275307
Mol Cell Biol. 2000 Feb;20(4):1436-47
pubmed: 10648628
J Virol. 2002 Feb;76(4):2009-13
pubmed: 11799198
Virology. 1993 Nov;197(1):459-62
pubmed: 8212585
Nucleic Acids Res. 1987 Jun 11;15(11):4491-511
pubmed: 3035496
J Virol. 2007 Sep;81(18):9653-64
pubmed: 17609267
J Virol. 1985 Feb;53(2):587-95
pubmed: 2982037
Nucleic Acids Res. 1986 Aug 11;14(15):6067-83
pubmed: 3018669
J Virol. 1988 Mar;62(3):732-43
pubmed: 2828668
Clin Exp Ophthalmol. 2010 Apr;38(3):309-13
pubmed: 20447128
Virology. 2008 May 25;375(1):13-23
pubmed: 18321553
Nat Cell Biol. 2005 May;7(5):493-500
pubmed: 15834407
Mol Cancer Ther. 2018 Aug;17(8):1637-1647
pubmed: 29769307
Nucleic Acids Res. 2017 Jul 27;45(13):8064-8078
pubmed: 28505309
J Infect Dis. 2008 Sep 1;198(5):659-63
pubmed: 18627246
Prog Retin Eye Res. 2013 Jan;32:88-101
pubmed: 22944008
PLoS Pathog. 2011 Oct;7(10):e1002278
pubmed: 21998580
J Virol. 2005 Oct;79(19):12487-94
pubmed: 16160176
J Virol. 2002 Jan;76(1):195-207
pubmed: 11739685
PLoS Pathog. 2009 Oct;5(10):e1000605
pubmed: 19798429
J Virol. 2006 Dec;80(23):11589-97
pubmed: 16987974
Invest Ophthalmol Vis Sci. 1995 Mar;36(3):614-21
pubmed: 7534282
Med Microbiol Immunol. 2011 Feb;200(1):61-8
pubmed: 20949280
Sci Adv. 2018 Jun 20;4(6):eaat1719
pubmed: 29938225
J Virol. 1997 Sep;71(9):6842-9
pubmed: 9261409
Cell Death Differ. 2003 Dec;10(12):1290-9
pubmed: 12934066
J Cell Sci. 2011 Jan 15;124(Pt 2):280-91
pubmed: 21172801
PLoS Pathog. 2011 Jun;7(6):e1002084
pubmed: 21698222
Nat Protoc. 2006;1(1):23-9
pubmed: 17406208
Cell Host Microbe. 2014 Mar 12;15(3):283-94
pubmed: 24629335
Antiviral Res. 2013 Nov;100(2):365-72
pubmed: 24075863
Mol Cancer Res. 2003 Aug;1(10):729-38
pubmed: 12939398
J Virol. 1999 Jan;73(1):650-7
pubmed: 9847370
Invest Ophthalmol Vis Sci. 2005 Feb;46(2):470-8
pubmed: 15671271
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5844-9
pubmed: 15824307
J Gen Virol. 1973 Dec;21(3):453-67
pubmed: 4357936
Mini Rev Med Chem. 2014;14(10):805-11
pubmed: 25138084
J Biol Chem. 2005 Aug 26;280(34):30336-41
pubmed: 15964848
Cell. 1982 Nov;31(1):89-97
pubmed: 6297756
PLoS Pathog. 2013;9(10):e1003652
pubmed: 24098119
BMC Biotechnol. 2006 Sep 22;6:40
pubmed: 16995942